Effects of RAGE Gene Polymorphisms on the Risk and Progression of Hepatocellular Carcinoma. Issue 34 (August 2015)

• Record Type: Journal Article
• Authors: Su, Shih-Chi; Hsieh, Ming-Ju; Chou, Ying-Erh; Fan, Wen-Lang; Yeh, Chao-Bin; Yang, Shun-Fa; Giovanni, Tarantino.
• Is Part Of: Medicine. Volume 94:Issue 34(2015)
• Publication Date: 2015-08
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000001396
• Languages: English
• ISSNs: 0025-7974

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Abstract</title> <p>Hepatocellular carcinoma (HCC) is a common malignancy of the liver, whose heterogeneous incidence reflects genetic variations among individuals in the main risk factors. The receptor for advanced glycosylation endproducts (RAGE) is a multiligand receptor and known to be implicated in various pathogenic conditions, such as diabetes, inflammatory disorder, Alzheimer disease, and cancer. In this study, the impact of <italic>RAGE</italic> gene polymorphisms on the susceptibility to hepatocarcinogenesis was explored. Four single-nucleotide polymorphisms (SNPs), rs184003 (1704G > T), rs1800624 (−374T > A), rs1800625 (−429T > C), and rs2070600 (Gly82Ser), as well as 1 gene polymorphism of <italic>RAGE</italic> gene, a 63 bp deletion allele (−407 to −345) were analyzed between 300 cancer-free subjects and 265 HCC cases. We detected a significant association of rs1800625 with the increased risk of HCC (odds ratio [OR], 2.565; 95% confidence interval [CI], 1.492–4.409 and adjusted odds ratio [AOR], 2.568; 95% CI, 1.418–4.653). However, patients who possess at least 1 polymorphic allele of rs1800625 are less prone to develop late-stage (stage III/IV, OR, 0.502; 95% CI, 0.243–1.037; <italic>P</italic> = 0.059 and AOR, 0.461; 95% CI, 0.219–0.970; <italic>P</italic> = 0.041) and large-size tumors (OR, 0.398; 95% CI, 0.183–0.864; <italic>P</italic> = 0.017 and AOR, 0.351; 95% CI, 0.157–0.781; <italic>P</italic> = 0.010). Furthermore, individuals bearing specific haplotypes of 4 RAGE SNPs tested are more inclined to have HCC. In conclusion, our data suggest a correlation of <italic>RAGE</italic> gene polymorphism rs1800625 with the early stage of liver tumorigenesis and implicate its protective role in the progression of HCC.</p> </sec> </abstract>